Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride

Open access
Jendle, J., Hyötyläinen, T., Orešič, M., Nyström, T. · 2021 · Cardiovascular Diabetology

Abstract

Background: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a treatment for fatty liver disease. The mechanisms behind these effects are still not fully elucidated. The aim of the study was to investigate whether treatment with liraglutide is associated with favourable metabolic changes in cases of both CV disease and fatty liver disease. Methods: In a prespecified post-hoc analysis of a double-blind, placebo-controlled trial in 62 individuals with type 2 diabetes (GLP-1 RA liraglutide or glimepiride, both in combination with metformin), we evaluated the changes in plasma molecular lipids and polar metabolites after 18 weeks of treatment. The lipids and polar metabolites were measured by using ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS). Results: In total, 340 lipids and other metabolites were identified, covering 14 lipid classes, bile acids, free fatty acids, amino acids and other polar metabolites. We observed more significant changes in the metabolome following liraglutide treatment compared to with glimepiride, particularly as regards decreased levels of cholesterol esters hexocyl-ceramides, lysophosphatidylcholines, sphingolipids and phosphatidylcholines with alkyl ether structure. In the liraglutide-treated group, lipids were reduced by approximately 15% from baseline, compared to a 10% decrease in the glimepiride group. At the pathway level, the liraglutide treatment was associated with lipid, bile acid as well as glucose metabolism, while glimepiride treatment was associated with tryptophan metabolism, carbohydrate metabolism, and glycerophospholipid metabolism. Conclusions: Compared with glimepiride, liraglutide treatment led to greater changes in the circulating metabolome, particularly regarding lipid metabolism involving sphingolipids, including ceramides. Our findings are hypothesis-generating and shed light on the underlying biological mechanisms of the CV benefits observed with GLP-1 RAs in outcome studies. Further studies investigating the role of GLP-1 RAs on ceramides and CV disease including fatty liver disease are warranted. Trial registration: NCT01425580

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-021-01431-2

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Heatmap depicting log2 transformed levels of metabolites at baseline and after treatment [glimepiride + metformin (G) vs. liraglutide + metformin (L)]. Groups were further divided into subjects with myocardial infarction (MI) or without MI (C, control)
Fig. 1 Heatmap depicting log2 transformed levels of metabolites at baseline and after treatment [glimepiride + metformin (G) vs. liraglutide + metformin (L)]. Groups were further divided into subjects with myocardial infarction (MI) or without MI (C, control)CC BY · PubMed Central
Fig. 2 A Heatmap demonstrating differences in lipids, at baseline, between individuals with (n = 21) or without myocardial infarction (MI) (n = 41). B Selected examples of lipids, i.e., ceramide [Cer(d18:1/24:1)], triacylglycerol [TG(56:3)] and phosphatidylethanolamine [PE(35:5)], showing significant differences at baseline between groups with or without MI, with adjusted p values marked to the boxplots
Fig. 2 A Heatmap demonstrating differences in lipids, at baseline, between individuals with (n = 21) or without myocardial infarction (MI) (n = 41). B Selected examples of lipids, i.e., ceramide [Cer(d18:1/24:1)], triacylglycerol [TG(56:3)] and phosphatidylethanolamine [PE(35:5)], showing significant differences at baseline between groups with or without MI, with adjusted p values marked to the boxplotsCC BY · PubMed Central
Fig. 3 A Heatmap of fold changes between treated groups [glimepiride (G) vs. liraglutide (L)]. B Selected examples of lipids, i.e., phosphatidylcholine [PC(36:4)], phosphatidylethanolamines [PE(18:1/8:2)], lysophosphatidylcoline [LPC(18:2)] and triacylglycerol [TG(18:0/18:1/20:4)], showing significant difference between treated groups [glimepiride (G) vs. liraglutide (L)], with adjusted p values marked to the boxplots
Fig. 3 A Heatmap of fold changes between treated groups [glimepiride (G) vs. liraglutide (L)]. B Selected examples of lipids, i.e., phosphatidylcholine [PC(36:4)], phosphatidylethanolamines [PE(18:1/8:2)], lysophosphatidylcoline [LPC(18:2)] and triacylglycerol [TG(18:0/18:1/20:4)], showing significant difference between treated groups [glimepiride (G) vs. liraglutide (L)], with adjusted p values marked to the boxplotsCC BY · PubMed Central
Fig. 4 Pathway analysis performed on the metabolomic data were done by both mummichog as well as with Gene Set Enrichment Analysis (GSEA)
Fig. 4 Pathway analysis performed on the metabolomic data were done by both mummichog as well as with Gene Set Enrichment Analysis (GSEA)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 27

Metadata

Authors
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T.
Affiliations
  • Örebro University (SE)
  • Karolinska Institutet (SE)
Corresponding author
Jendle, J.
Venue
Cardiovascular Diabetology
Published
2021-12
Volume
20
Issue
1
Pages
237-237
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4200606167
Cited by
27
References
48
Citations by year
2026: 3 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 4
FWCI
3.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Novo Nordisk
  • Örebro University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
liraglutide, glimepiride, type 2 diabetes, pharmacometabolomics, GLP-1 receptor agonists, plasma lipid metabolism, sphingolipids, ceramide, lysophosphatidylcholine, bile acids, hepatic steatosis, cardiovascular disease, metformin, tryptophan metabolism, glycerophospholipid metabolism, glucose metabolism
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Lipidomics, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Chromatography, High Pressure Liquid, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Lipids, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Time Factors, Biomarkers, Treatment Outcome, Spectrometry, Mass, Electrospray Ionization, Incretins, Metabolomics, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. https://app.cochat.ai/papers/10.1186/s12933-021-01431-2
The paper
Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021). Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01431-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.